BY OUR PLATFORMS
BY THERAPEUTIC AREA
25 January 2021 - 27 January 2021
Flavia De Santis obtained her master's degree in medical biotechnologies from the University of Bari (Italy). She pursued her scientific education at the Institute Curie (Paris), obtaining a Ph.D. in neuronews. During her doctorate, she focused her research on the study of the mechanisms underlying the establishment of neural circuits, in zebrafish and, in parallel, she worked on the implementation of innovative CRISPR/Cas9-based genome engineering approaches. She was recently awarded a Torres Y Quevedo post-doctoral fellowship in order to join Zeclinics and develop zebrafish genetics models for biopharmaceutical
She will participate in SLAS 2021 where she will present a poster entitled ZeGenesis, an innovative CRISPR/Cas9-based platform to boost target and drug discovery in Zebrafish”. She will describe how, aZeclinics, we support the drug-discovery pipelines of pharmaceutical companies by combining state-of-the-art genome editing strategies with high-throughput imaging systems.